IBRXImmunityBio, Inc.

IBRX Stock Price, Valuation & Chart | ImmunityBio, Inc.

Compare

$7.950+0.08 (+1.02%)

At close · 02 Sept 2026, 08:00 pm

Sector: Healthcare Industry: Biotechnology IBRX intrinsic value IBRX calculated fair value vs price

Overview Financials Dividends Ratios

IBRX Historical price chart

IBRX Key Stats

Fair Value

Disclaimer

Disclaimer: This fair value estimate is for informational purposes only and should not be considered as investment advice. Fair value calculations are based on DCF (Discounted Cash Flow), P/E Multiple, and P/S Multiple models and assumptions that may not reflect actual market conditions. Always conduct your own research and consult with a financial advisor before making investment decisions.

Unlock

Market Capitalization8.33B

PE Ratio-8.2

EPS-0.97

Trading Volume7.20M

Today's High/Low8.28/7.75

Dividend Yield0.00

52 Week High/Low12.43/1.95

Shares Outstanding1.05B

IBRX Financial Statement

IBRX Analyst ratings

IBRX Analysis & performance metrics

IBRX Company profile

ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy…

ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The company also develops therapeutic agents,…

IBRX Management team

Name

Position

Jason R. Liljestrom J.D.

General Counsel & Corporate Secretary

Leonard S. Sender M.D.

Chief Medical Officer of Liquid Tumors & Cell Therapy

David C. SachsCFO

Chief Financial Officer

Barry J. Simon M.D.CTO

Chief Corporate Affairs Officer & Director

Enrique Diloné Ph.D., RACCTO

Chief Technology Officer

Sandeep K. Reddy M.D.

Chief Medical Officer

Richard Gerald AdcockCEO

President, Chief Executive Officer & Director

Sarah Singleton

Chief Communications Officer & Head of Patient Advocacy

Name

Position

Jason R. Liljestrom J.D.

General Counsel & Corporate Secretary

Leonard S. Sender M.D.

Chief Medical Officer of Liquid Tumors & Cell Therapy

David C. SachsCFO

Chief Financial Officer

Barry J. Simon M.D.CTO

Chief Corporate Affairs Officer & Director

Enrique Diloné Ph.D., RACCTO

Chief Technology Officer

Sandeep K. Reddy M.D.

Chief Medical Officer

Richard Gerald AdcockCEO

President, Chief Executive Officer & Director

Sarah Singleton

Chief Communications Officer & Head of Patient Advocacy

Management Team

Jason R. Liljestrom J.D.

General Counsel & Corporate Secretary

Leonard S. Sender M.D.

Chief Medical Officer of Liquid Tumors & Cell Therapy

David C. SachsCFO

Chief Financial Officer

Barry J. Simon M.D.CTO

Chief Corporate Affairs Officer & Director

Enrique Diloné Ph.D., RACCTO

Chief Technology Officer

Sandeep K. Reddy M.D.

Chief Medical Officer

Richard Gerald AdcockCEO

President, Chief Executive Officer & Director

Sarah Singleton

Chief Communications Officer & Head of Patient Advocacy

Management

Jason R. Liljestrom J.D.

General Counsel & Corporate Secretary

Leonard S. Sender M.D.

Chief Medical Officer of Liquid Tumors & Cell Therapy

David C. SachsCFO

Chief Financial Officer

Barry J. Simon M.D.CTO

Chief Corporate Affairs Officer & Director

Enrique Diloné Ph.D., RACCTO

Chief Technology Officer

Sandeep K. Reddy M.D.

Chief Medical Officer

Richard Gerald AdcockCEO

President, Chief Executive Officer & Director

Sarah Singleton

Chief Communications Officer & Head of Patient Advocacy

Total 8 executives

IBRX Frequently asked questions

What is ImmunityBio, Inc. (IBRX) Stock Price?

Current stock price of ImmunityBio, Inc. (IBRX) stock is $7.950. The stock price is +1.02% higher in the session. The intraday range can be seen from this page. Volume of ImmunityBio, Inc. (IBRX) stock is 7.20M.

Last updated at 02 Sept 2026, 08:00 pm.

Why is the ImmunityBio, Inc. (IBRX) stock price going up or down today?

The stock price of ImmunityBio, Inc. (IBRX) can change with earnings, company news, and overall market sentiment. ImmunityBio, Inc. operates in the Healthcare / Biotechnology market, so sector-wide moves can also affect the share price. Use the live price, percentage change, and volume on this page to judge whether a move looks meaningful.

Is the ImmunityBio, Inc. stock expensive at its current price?

Whether ImmunityBio, Inc. looks expensive depends on valuation metrics versus its growth outlook. The P/E ratio shown for IBRX on this page is -8.20. EPS on this page is -0.97. Compare those figures with peers and growth expectations before deciding if the current ImmunityBio, Inc. price is justified.

How has the stock price of ImmunityBio, Inc. (IBRX) performed historically?

Historical performance for ImmunityBio, Inc. (IBRX) is shown on the price chart on this page. Review multi-period moves alongside volume to see how IBRX reacted to past earnings and market events.

Should I buy ImmunityBio, Inc. (IBRX) stock, at this price?

Buying ImmunityBio, Inc. (IBRX) depends on your risk tolerance, time horizon, and portfolio needs. As a Healthcare name, weigh the live quote, key stats, and valuation links on this page rather than a single price point.